EMA Committee Backs Infliximab Biosimilar Product FlixabiEMA Committee Backs Infliximab Biosimilar Product Flixabi

Studies show 'comparable quality, safety and efficacy' to the reference product Remicade (infliximab), the committee noted. International Approvals
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Rheumatology News Alert Source Type: news